CERVOMED INC (CRVO)
US15713L1098 - Common Stock
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for...
What's going on in today's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility, balance, a
Gapping stocks in Tuesday's session
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
Get insights into the top gainers and losers of Tuesday's pre-market session.
Top movers in Tuesday's pre-market session
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and...
Friday Sector Leaders: Biotechnology, Apparel Stores
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On...
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies...
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their...
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust...
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured...
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”...
Thursday Sector Leaders: Semiconductors, Biotechnology Stocks
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CRVO Stock Earnings: CervoMed Beats EPS, Beats Revenue for Q2 2024
CRVO stock results show that CervoMed beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We have all of the biggest pre-market stock movers that traders are going to want to read about on Tuesday!
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed to Participate in the Emerging Growth Conference
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 ...
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023
CRVO stock results show that CervoMed missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025.
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with...
CervoMed Becomes Oversold (CRVO)
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024
CRVO stock results show that CervoMed missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy...
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and...